ATE265432T1 - 3-amino-5-carboxy-substituierte piperidine und 3- amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten - Google Patents

3-amino-5-carboxy-substituierte piperidine und 3- amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten

Info

Publication number: ATE265432T1
Authority: AT; Austria
Prior art keywords: carboxy; amino; substituted; alkylene; methoxy
Prior art date: 1993-09-17

Application number

AT94926394T

Other languages

English (en)

Inventor

Masaya Ikunaka

Yuuji Shishido

Masami Nakane

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-17

Filing date

1994-09-13

Publication date

2004-05-15

1994-09-13 Application filed by Pfizer filed Critical Pfizer

2004-05-15 Application granted granted Critical

2004-05-15 Publication of ATE265432T1 publication Critical patent/ATE265432T1/de

Links

102000003141 Tachykinin Human genes 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
150000003053 piperidines Chemical class 0.000 title 1
150000003235 pyrrolidines Chemical class 0.000 title 1
108060008037 tachykinin Proteins 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
102100024304 Protachykinin-1 Human genes 0.000 abstract 1
101800003906 Substance P Proteins 0.000 abstract 1
206010047700 Vomiting Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000007815 allergy Effects 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000002541 furyl group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
125000001624 naphthyl group Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

AT94926394T 1993-09-17 1994-09-13 3-amino-5-carboxy-substituierte piperidine und 3- amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten ATE265432T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP25506493		1993-09-17
PCT/JP1994/001514 WO1995007886A1 (en)	1993-09-17	1994-09-13	3-amino-5-carboxy-substituted piperidines and 3-amino-4-carboxy-substituted pyrrolidines as tachykinin antagonists

Publications (1)

Publication Number	Publication Date
ATE265432T1 true ATE265432T1 (de)	2004-05-15

Family

ID=17273646

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94926394T ATE265432T1 (de)	1993-09-17	1994-09-13	3-amino-5-carboxy-substituierte piperidine und 3- amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten

Country Status (9)

Country	Link
EP (1)	EP0719253B1 (de)
AT (1)	ATE265432T1 (de)
CA (1)	CA2171637C (de)
DE (1)	DE69433744T2 (de)
DK (1)	DK0719253T3 (de)
ES (1)	ES2217269T3 (de)
FI (1)	FI112472B (de)
PT (1)	PT719253E (de)
WO (1)	WO1995007886A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2205016A1 (en) *	1994-11-10	1996-05-23	Hans-Jurgen Ernst Hess	Nk-1 receptor antagonists for the treatment of eye disorders
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
BR0015320A (pt)	1999-11-03	2002-07-09	Albany Molecular Res Inc	Composto, composição, métodos de tratamento de um distúrbio que e criado pela, ou é dependente da, disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, para inibir a captação da serotonina, da dopamina e de norepinefrina sinápticas em um paciente em necessidade destes, e, kit
CN100430401C (zh)	2000-07-11	2008-11-05	Amr科技公司	新的4-苯基取代的四氢异喹啉类化合物及其治疗用途
UA91341C2 (ru)	2004-07-15	2010-07-26	Амр Текнолоджи, Інк.	Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
US8362075B2 (en)	2005-05-17	2013-01-29	Merck Sharp & Dohme Corp.	Cyclohexyl sulphones for treatment of cancer
JP5258561B2 (ja)	2005-07-15	2013-08-07	アルバニーモレキュラーリサーチ，インコーポレイテッド	アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
BRPI0616463A2 (pt)	2005-09-29	2011-06-21	Merck & Co Inc	composto, composição farmacêutica, e, uso de um composto
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
EP2083831B1 (de)	2006-09-22	2013-12-25	Merck Sharp & Dohme Corp.	Verfahren zur behandlung von fettsäure-synthese-hemmern
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja)	2007-01-10	2011-01-12	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー	ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
CA2682727C (en)	2007-04-02	2016-03-22	Banyu Pharmaceutical Co., Ltd.	Indoledione derivative
AU2008269154B2 (en)	2007-06-27	2014-06-12	Merck Sharp & Dohme Llc	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh)	2008-03-03	2011-04-13	泰格尔医药科技公司	酪氨酸激酶抑制剂
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en)	2009-04-01	2014-04-08	Merck Sharp & Dohme Corp.	Inhibitors of AKT activity
EP2429296B1 (de)	2009-05-12	2017-12-27	Albany Molecular Research, Inc.	7-([1,2,4,]triazol[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorphenyl)-1,2,3,4- tetrahydroisochinolin und seine verwendung
US8815894B2 (en)	2009-05-12	2014-08-26	Bristol-Myers Squibb Company	Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
AU2010247849B2 (en)	2009-05-12	2015-11-19	Albany Molecular Research, Inc.	Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
JP5099731B1 (ja)	2009-10-14	2012-12-19	メルク・シャープ・アンド・ドーム・コーポレーション	ｐ５３活性を増大する置換ピペリジン及びその使用
US8999957B2 (en)	2010-06-24	2015-04-07	Merck Sharp & Dohme Corp.	Heterocyclic compounds as ERK inhibitors
US8518907B2 (en)	2010-08-02	2013-08-27	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
US9029341B2 (en)	2010-08-17	2015-05-12	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
WO2012027236A1 (en)	2010-08-23	2012-03-01	Schering Corporation	NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (de)	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Indazolderivate als erk-hemmer
EP2615916B1 (de)	2010-09-16	2017-01-04	Merck Sharp & Dohme Corp.	Kondensierte pyrazolderivate als neue erk-hemmer
US9260471B2 (en)	2010-10-29	2016-02-16	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US9351965B2 (en)	2010-12-21	2016-05-31	Merck Sharp & Dohme Corp.	Indazole derivatives useful as ERK inhibitors
US20140045832A1 (en)	2011-04-21	2014-02-13	Piramal Enterprises Limited	Insulin-Like Growth Factor-1 Receptor Inhibitors
EP2770987B1 (de)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Neue verbindungen als erk-hemmer
EP2844261B1 (de)	2012-05-02	2018-10-17	Sirna Therapeutics, Inc.	Sina-zusammensetzungen
CA2882950A1 (en)	2012-09-28	2014-04-03	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
MX363243B (es)	2012-11-28	2019-03-14	Merck Sharp & Dohme	Composiciones para tratar cáncer y usos de dichas composiciones.
TW201429969A (zh)	2012-12-20	2014-08-01	Merck Sharp & Dohme	作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (de)	2013-01-30	2018-05-02	Merck Sharp & Dohme Corp.	2,6,7,8-substituierte purine als hdm2-inhibitoren
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
EP3525785A4 (de)	2016-10-12	2020-03-25	Merck Sharp & Dohme Corp.	Kdm5-inhibitoren
US10947234B2 (en)	2017-11-08	2021-03-16	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
WO2019094312A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
US11981701B2 (en)	2018-08-07	2024-05-14	Merck Sharp & Dohme Llc	PRMT5 inhibitors
WO2020033282A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
CN112805006B (zh)	2018-08-07	2024-09-24	默沙东有限责任公司	Prmt5抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991009844A1 (en) *	1990-01-04	1991-07-11	Pfizer Inc.	Substance p antagonists
US5202344A (en) *	1990-12-11	1993-04-13	G. D. Searle & Co.	N-substituted lactams useful as cholecystokinin antagonists
PL170525B1 (en) *	1991-05-22	1996-12-31	Pfizer	Method of obtaining novel derivatives of 3-amino quinuclidine
DK0589924T3 (da) *	1991-06-20	1996-09-30	Pfizer	Fluoralkoxybenzylaminoderivater af nitrogenholdige heterocyclusser
JP2656702B2 (ja) *	1992-03-23	1997-09-24	ファイザー製薬株式会社	ペプチド性キヌクリジン
JP2656700B2 (ja) *	1992-10-28	1997-09-24	ファイザー製薬株式会社	置換キヌクリジン誘導体
US5340826A (en) *	1993-02-04	1994-08-23	Pfizer Inc.	Pharmaceutical agents for treatment of urinary incontinence

1994
- 1994-09-13 CA CA002171637A patent/CA2171637C/en not_active Expired - Fee Related
- 1994-09-13 AT AT94926394T patent/ATE265432T1/de not_active IP Right Cessation
- 1994-09-13 EP EP94926394A patent/EP0719253B1/de not_active Expired - Lifetime
- 1994-09-13 ES ES94926394T patent/ES2217269T3/es not_active Expired - Lifetime
- 1994-09-13 PT PT94926394T patent/PT719253E/pt unknown
- 1994-09-13 WO PCT/JP1994/001514 patent/WO1995007886A1/en active IP Right Grant
- 1994-09-13 DE DE69433744T patent/DE69433744T2/de not_active Expired - Fee Related
- 1994-09-13 DK DK94926394T patent/DK0719253T3/da active
1996
- 1996-03-15 FI FI961239A patent/FI112472B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
FI112472B (fi)	2003-12-15
FI961239A (fi)	1996-03-15
ES2217269T3 (es)	2004-11-01
PT719253E (pt)	2004-07-30
FI961239A0 (fi)	1996-03-15
EP0719253A1 (de)	1996-07-03
CA2171637A1 (en)	1995-03-23
DE69433744T2 (de)	2004-10-14
CA2171637C (en)	2000-05-23
WO1995007886A1 (en)	1995-03-23
DK0719253T3 (da)	2004-07-26
DE69433744D1 (de)	2004-06-03
EP0719253B1 (de)	2004-04-28

Publication	Publication Date	Title
ATE265432T1 (de)	2004-05-15	3-amino-5-carboxy-substituierte piperidine und 3- amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten
NO20013768L (no)	2001-10-01	Kjemiske forbindelser
ATE244007T1 (de)	2003-07-15	Indol-derivate und ihre anwendung als mcp-1 antagonisten
ATE251610T1 (de)	2003-10-15	Indolderivate als mcp-1 rezeptor antagonisten
NO2005023I1 (no)	2005-10-03	Palonosetron HCI
FI950309A0 (fi)	1995-01-24	Proliiniamidijohdannaisia
DE69915004D1 (de)	2004-04-01	5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
ATE221064T1 (de)	2002-08-15	Cyclische amidderivate als neurokinin a antagonisten
DE60041973D1 (de)	2009-05-20	Substituierte piperidin-verbindungen als modulatoren der chemokine receptor aktivität
ATE219766T1 (de)	2002-07-15	N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
DK0610487T3 (da)	2000-05-15	Nye aminosyrederivater, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser
IS6257A (is)	2002-01-31	Frumuviðloðunartálmar
DK0807633T3 (da)	2002-11-25	Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner
ATE260897T1 (de)	2004-03-15	3-(4-subst.-piperidinyl-1)-1-(3,4- dichlorophenyl)propylcarbamate und -harnstoffe und andere derivative als neue neurokinin- antagonisten
EA200400467A1 (ru)	2004-08-26	Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
ATE377602T1 (de)	2007-11-15	Morphinanderivate und ihre medizinische anwendung
NO20001483L (no)	2000-05-23	Nye NPY-agonister
NZ333513A (en)	2000-04-28	1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
DE69915687D1 (de)	2004-04-22	Heterocyclische amide als inhibitoren von faktor xa
DE69613457D1 (de)	2001-07-26	5-(4-subst.-piperidinyl-1)-3-aryl-pentansäure derivate als tachykinin rezeptor antagonisten
DE3763863D1 (de)	1990-08-30	Substituierte tetrahydro-3-pyridincarbonsaeuren, ihre ester und amide als cholinergische mittel.
WO1998031704A3 (en)	1998-09-11	Tachykinin antagonists
DE69332366D1 (de)	2002-11-14	Arylsubstituierte heterocyclische Verbindungen
MY115372A (en)	2003-05-31	1 4- dihydropyridine compounds
DE69329184D1 (de)	2000-09-14	Alkylsubstituierte heterocyclische Verbindungen

Legal Events

Date	Code	Title	Description
2004-11-15	UEP	Publication of translation of european patent specification	Ref document number: 0719253 Country of ref document: EP
2006-06-15	REN	Ceased due to non-payment of the annual fee

Date

Code

Title

Description

2004-11-15

UEP

Publication of translation of european patent specification

Ref document number: 0719253

Country of ref document: EP

2006-06-15

REN

Ceased due to non-payment of the annual fee